Saturday, September 30, 2023
SOPHiA GENETICS, a cloud-native software company specializing in data-driven medicine, has announced that Shaare Zedek, Jerusalem's largest multi-disciplinary medical center, has integrated the SOPHiA DDM™ Platform into its operations. This platform empowers Shaare Zedek to enhance its understanding and treatment of myeloid disorders, contributing to the development of precision medicine applications.
Myeloid disorders, stemming from hematopoietic disruptions in the myeloid lineage, pose significant challenges due to their diverse genetic mutations and classifications. Timely, cost-effective, and reliable sequencing strategies are essential in evolving treatment and therapy techniques for these disorders, which affect millions of people worldwide.
With a legacy dating back to 1902, Shaare Zedek Medical Center has established itself as a leader in medical research and care in Jerusalem. The adoption of SOPHiA GENETICS technology aligns the center with the latest guidelines from the European Hematology Association (EHA) and reinforces its position at the forefront of medical advancements in Israel.
Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS, emphasized the rapid progress in targeted therapies for myeloid disorders. He noted that the SOPHiA DDM™ Platform would enable Shaare Zedek to stay updated with international recommendations while advancing its research efforts to benefit the local community.
The SOPHiA DDM™ Platform leverages next-generation sequencing (NGS) and artificial intelligence (AI) to efficiently analyze and interpret complex NGS data for researchers. This platform provides rapid insights, enabling clinical researchers to make data-driven recommendations within days.
Furthermore, the SOPHiA DDM™ Platform simplifies data reproducibility, supporting the acceleration of research efforts at Shaare Zedek Medical Center. The platform allows the center to retain complete ownership of its database, facilitating ongoing research and expertise development.